Catalyst Brief

← Calendar

Readoutin 135d

Amgen — Maridebart Cafraglutide

Phase 3 primary completion: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight.

Date
Apr 2027
Type
Readout
Indication
Obesity

Source ↗Add to calendar

Date history

Jan 1, 2027 → Apr 1, 2027Nov 17, 2026
Apr 1, 2027 → Jan 1, 2027Nov 17, 2026
Jan 1, 2027 → Apr 1, 2027Nov 17, 2026

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Amgen

  1. Jan2027